AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Maravai LifeSciences Holdings, Inc.
Video analysis: MRVI
All videosNo video analysis for this stock yet. Request one from our team.
News: MRVI
Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel
Maravai (MRVI) is evolving into an integrated supplier for the in vitro transcription (IVT) RNA workflow, embedding products across the customer lifecycle. Q2 2026 marked a profitability inflection, with gross margins rising to 40.1% and Adjusted EBITDA turning positive, reflecting successful cost realignment and segment-level improvement. TriLink's integrated GMP enzyme facility and ModTail technology strengthen customer stickiness, while Cygnus provides recurring, high-margin biologics safety earnings.
Dimensional Fund Advisors LP Boosts Holdings in Maravai LifeSciences Holdings, Inc. $MRVI
Dimensional Fund Advisors LP boosted its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) by 64.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,418,597 shares of the company's stock after buying an additional 558,050 shares during the
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Down – Here’s Why
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) shares gapped down before the market opened on Friday. The stock had previously closed at $6.25, but opened at $5.60. Maravai LifeSciences shares last traded at $5.6880, with a volume of 683,238 shares. Key Headlines Impacting Maravai LifeSciences Here are the key news stories impacting
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
Maravai LifeSciences Q2 Earnings Call Highlights
Maravai LifeSciences (NASDAQ: MRVI) reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast. Revenue for the quarter was $51.4 million, up 9% from the prior-year period. CEO Bernd Brust said the performance extended momentum established in the first quarter, led by
Maravai LifeSciences Q2 Earnings Call Highlights
Maravai LifeSciences NASDAQ: MRVI reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast.
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.
Maravai LifeSciences Reports Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million; Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 milli.
